FDA 510(k) EXEMPTION OF 62 CLASS II DEVICES ON JAN. 21 BRINGS TOTAL TO 636; RULE INCLUDES 30 IVDs, BUT DOES NOT APPLY TO POINT-OF-CARE TEST SYSTEMS
This article was originally published in The Gray Sheet
Executive SummaryFDA exemption of 62 Class II devices from 510(k) review in a Jan. 21 final rule brings to 636 the total number of products that no longer require premarket evaluation. The final rule was published two days after the 60-day deadline stipulated in the FDA Modernization Act, which was signed into law Nov. 21.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.